Salehi Zahra, Doosti Rozita, Beheshti Masoumeh, Janzamin Ehsan, Sahraian Mohammad Ali, Izad Maryam
Immunology Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
PLoS One. 2016 Jul 28;11(7):e0159565. doi: 10.1371/journal.pone.0159565. eCollection 2016.
Recent evidence points to a pathogenic role for CD8+ cytotoxic T (Tc) cells in Multiple sclerosis (MS). Based on cytokine profile, Tc cells can be divided into different subsets: IFN-γ (Tc1), IL-4 (Tc2), IL-10 (Tc10), IL-17 (Tc17), IL-21 (Tc21), IL-22 (Tc22) and TNF-α producing cells. In this study we evaluated the frequency of Tc cell subsets and the serum level of Tc17 differentiation cytokines in MS patients with different clinical patterns. We analyzed Tc cell subsets percentage in peripheral blood of relapsing-remitting (RRMS) (n = 28), secondary-progressive (SPMS) (n = 10) and primary-progressive (PPMS) (n = 4) MS patients in comparison to healthy controls (n = 15) using flow cytometry. Serum level of TGF-β, IL-6 and IL-23 were measured by ELISA. We showed elevated levels of Tc1 and Tc17 cells in SPMS and RRMS patients in relapse phase, respectively (P = 0.04). Interestingly, the percentage of TNF-α producing CD8+ T cells in relapse and remission phase of RRMS and SPMS patients were higher than controls (P = 0.01, P = 0.004, P = 0.01, respectively) and Tc21 increased in remission phase of RRMS compared to SPMS (P = 0.03). We also found higher frequency of CD8+ IFN-γ+ TNF-α+ IL-17+ T cells in relapse phase of RRMS compared to remission phase, SPMS patients and controls (P = 0.01, P = 0.004 and P = 0.02, respectively). TGF- β increased in sera of RRMS patients in remission phase (P = 0.03) and SPMS (P = 0.05) compared to healthy subjects. Increased level of Tc17 and CD8+ IFN-γ+ TNF-α+ IL-17+ T cells in relapse phase highlights the critical role of IL-17 in RRMS pathogenesis.
近期证据表明,CD8 + 细胞毒性T(Tc)细胞在多发性硬化症(MS)中具有致病作用。根据细胞因子谱,Tc细胞可分为不同亚群:产生干扰素-γ(Tc1)、白细胞介素-4(Tc2)、白细胞介素-10(Tc10)、白细胞介素-17(Tc17)、白细胞介素-21(Tc21)、白细胞介素-22(Tc22)的细胞以及产生肿瘤坏死因子-α的细胞。在本研究中,我们评估了不同临床类型的MS患者中Tc细胞亚群的频率以及Tc17分化细胞因子的血清水平。我们使用流式细胞术分析了复发缓解型(RRMS)(n = 28)、继发进展型(SPMS)(n = 10)和原发进展型(PPMS)(n = 4)MS患者外周血中Tc细胞亚群的百分比,并与健康对照(n = 15)进行比较。通过酶联免疫吸附测定法(ELISA)检测血清中转化生长因子-β(TGF-β)、白细胞介素-6和白细胞介素-23的水平。我们发现,SPMS患者和处于复发期的RRMS患者中,Tc1和Tc17细胞水平分别升高(P = 0.04)。有趣的是,RRMS和SPMS患者在复发期和缓解期产生肿瘤坏死因子-α的CD8 + T细胞百分比均高于对照组(分别为P = 0.01、P = 0.004、P = 0.01),且与SPMS相比,RRMS患者在缓解期Tc21增加(P = 0.03)。我们还发现,与缓解期、SPMS患者及对照组相比,RRMS患者在复发期CD8 + 干扰素-γ + 肿瘤坏死因子-α + 白细胞介素-17 + T细胞的频率更高(分别为P = 0.01、P = 0.004和P = 0.02)。与健康受试者相比,RRMS患者缓解期(P = 0.03)和SPMS患者(P = 0.05)血清中TGF-β升高。复发期Tc17和CD8 + 干扰素-γ + 肿瘤坏死因子-α + 白细胞介素-17 + T细胞水平升高突出了白细胞介素-17在RRMS发病机制中的关键作用。